Gynecologic oncology in 2024: breakthrough trials and evolving treatment strategies for cervical, uterine corpus, and ovarian cancers

• Published in: Journal of gynecologic oncology Vol. 36; no. 1; pp. e72 - 15
• Main Authors: Lee, Sung Jong, Yoo, Ji Geun, Kim, Jin Hwi, Park, Jeong-Yeol, Lee, Jung-Yun, Lee, Yoo-Young, Suh, Dong Hoon
• Format: Journal Article
• Language: English
• Published: Korea (South) Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology 01.01.2025; 대한부인종양학회
• Subjects: Clinical Trials as Topic; Female; Humans; Ovarian Neoplasms - therapy; Review; Uterine Cervical Neoplasms - pathology; Uterine Cervical Neoplasms - therapy; Uterine Neoplasms - therapy; 산부인과학; Immunoconjugates; Molecular Targeted Therapy; Gynecologic Neoplasms; Immunotherapy; Poly(ADP-Ribose) Polymerase Inhibitor
• ISSN: 2005-0380; 2005-0399; 2005-0399
• DOI: 10.3802/jgo.2025.36.e72

This review summarized the results of clinical trials in 2024 that were believed to have a significant impact on clinical practice in the field of gynecologic oncology. The SHAPE trial, INTERLACE and KEYNOTE-A18 trials, and BEATcc and COMPASSION-16 trials were included in early-stage, locally advanced, and recurrent/metastatic cervical cancer, respectively. For uterine corpus cancer, updated survival data of the four trials (NRG-GY018, RUBY, AtTEnd, DUO-E) for endometrial cancer and the first survival data of LMS-04 trial for leiomyosarcoma were described. For ovarian cancer, the final overall survival results of PRIMA study were followed by DUO-O, ATHENA-combo, and FIRST-ENGOT-OV44 trial in different disease conditions. Finally, the results of DESTINY-PanTumor02, a basket trial of trastuzumab deruxtecan, were briefly addressed.